Nerea Bilbao-Aldaiturriaga

Nerea Bilbao-Aldaiturriaga

Auto-generated profile, based on publicly available information

Nerea Bilbao-Aldaiturriaga

Pediatric Oncology Group, Biobizkaia Health Research Institute, Barakaldo, Basque Country, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ALAne Larrabeiti-Etxebarria
Ane Larrabeiti-Etxebarria
NBNerea Bilbao-Aldaiturriaga
Nerea Bilbao-Aldaiturriaga
JMJavier Arzuaga Méndez
Javier Arzuaga Méndez
MMMaialen Martin-Arruti
Maialen Martin-Arruti
LCLuca Cozzuto
Luca Cozzuto
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
Despite being considered a single disease, Diffuse Large B Cell Lymphoma (DLBCL) presents with variable backgrounds, which results in heterogeneous outcomes among patients, with 40% of them still having primary refractory disease or relapse. Thus, novel biomarkers are needed. In addition, multiple factors regarding its pathogenesis remain unclear. In this context, recent investigations point to the relevance of microRNAs (miRNAs) in cancer. However, regarding DLBCL, there is inconsistency in the data reported. Therefore, in this work, the main goals were to determine a miRNA set with utility as biomarkers for DLBCL diagnosis, classification, prognosis and treatment response, as well as to decipher the mechanism of action of deregulated miRNAs in the origin of the disease. We analyzed miRNA expression in a cohort of 78 DLBCL patients and 17 controls using small RNA sequencing and performed a miRNA-mRNA interaction network analysis. This way, we were able to define new miRNA expression signatures for diagnosis, classification, treatment response and prognosis, and we identified plausible mechanisms of action by which deregulated miRNAs could be involved in DLBCL pathogenesis. In summary, our study remarks that miRNAs could play an important role in DLBCL.


10 November 2025 in Molecular and Cellular Pediatrics
Verified
Journal Article
Open access
PDF file
UIUnai Illarregi
Unai Illarregi
NBNerea Bilbao-Aldaiturriaga
Nerea Bilbao-Aldaiturriaga
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
IEIvan Martinez de Estibariz
Ivan Martinez de Estibariz
JMJavier Arzuaga Méndez
Javier Arzuaga Méndez
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
Background: B-cell Acute Lymphoblastic Leukemia (B-ALL) remains an important cause of cancer-related death in children. Therefore, accurate identification at diagnosis of patients at high risk of relapse is crucial. In this context, long non-coding RNAs (lncRNAs) could be novel candidates with great potential. Hence, the aim of this study was to identify new prognostic biomarkers in pediatric B-ALL through an RNA sequencing (RNA-seq) approach that allows the detailed exploration of a wide range of lncRNAs. Methods: Total RNA from two cohorts of B-ALL patients (C1 with 50 Spanish patients, and C2 with 72 Canadian patients) was sequenced with a depth of approximately 150 million paired-reads using Illumina technology. All protein coding and non-coding genes included in lncRNAKB annotation were studied to develop a gene expression-based 5-year Event Free Survival (EFS) prediction model. Results: First, univariate Cox proportional hazards analyses identified 48 genes significantly associated with higher EFS risk in both cohorts. From these, ALASSO regression selected five genes, all of which are lncRNAs, as the most informative to develop the prediction model, which we have called surviBALL. Stratification of patients into three risk groups according to the surviBALL model revealed significantly poorer EFS in high-risk patients across C1, C2, and the integrated C1 + C2 cohort ( P < 0.001). Validation in an independent cohort of 177 publicly available B-ALL samples confirmed surviBALL’s prediction capacity ( P = 2.80 × 10 − 4 ) and its independence of both subtype and MRD. Conclusions: These findings suggest that surviBALL has the potential to complement current risk stratification approaches, particularly by identifying patients at high risk of relapse at diagnosis. As a hypothesis-generating proof of concept, this study highlights the promise of more personalized treatment strategies and warrants further validation in independent cohorts.

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
IEIván Martínez de Estíbariz
Iván Martínez de Estíbariz
UIUnai Illarregi
Unai Illarregi
DSDaniel Sinnett
Daniel Sinnett
AGAngela Gutiérrez-Camino
Angela Gutiérrez-Camino
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
Background: Advances in multi-omic studies have improved medulloblastoma (MB) characterization, yet novel molecular biomarkers are needed to refine tumor biology and therapeutic strategies. Current profiling mainly targets the protein-coding genome, while the potential of noncoding regions remains unexplored. This study aims to identify long noncoding RNAs (lncRNAs), emerging as crucial regulators in MB, as potential key biomarkers specific to molecular group, enhancing understanding of MB’s genomic landscape. Methods: RNA-seq data from 54 Spanish MB patients (C1) and 207 public samples (C2) were analyzed to profile lncRNAs. Expression and Weighted Gene Coexpression Network (WGCNA) analyses were performed to identify lncRNA-oncogene interactions. Group-specific interactions were examined to infer their role in MB pathogenesis and highlight potential lncRNA involvement in disease mechanisms. Results: LncRNA expression profiles identified 4 clusters corresponding to the MB molecular groups, confirming their potential as biomarkers. Expression and WGCNA analyses revealed group-specific lncRNAs for Sonic hedgehog (SHH), Group 3 (Gr3), and Group 4 (Gr4) MB. Lnc-SMARCA2 was exclusively upregulated in SHH MB, and associated with ATOH1 and PDLIM3, key cilium regulators of this group’s cell of origin. In Gr4 MB, MGC32805 and LOC107986446 were upregulated and linked to SNCAIP, potentially influencing PRDM6 activation via enhancer hijacking. Additionally, a 5-lncRNA signature linked to phototransduction was exclusive to Gr3, offering insights into its lineage switch and molecular regulation. Conclusions: Lnc-SMARCA2 and, MGC32805 and LOC107986446, are exclusively deregulated in SHH and Gr4 MB, respectively, and directly associated with group-specific MB oncogenes, representing promising novel biomarkers and therapeutic targets in MB.